A Systematic Review and Meta‐Analysis to Assess Patient‐Reported Outcomes after Lung Cancer Surgery

Gazala, Sayf; Pelletier, Jean-Sébastien; Storie, Dale; Johnson, Jeffrey; Kutsogiannis, Demetrios J.; Bédard, Éric

doi:10.1155/2013/789625

Cited by 24 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the treatment patterns were different between SCLC and NSCLC patients, especially the chemotherapy (Kuwabara et al 2009), as well as molecular targeted therapy (Lauro et al 2014;Asai et al 2014). The most effective treatment for early NSCLC is surgical resection (Gazala et al 2013). However, nearly 2/3 of patients with NSCLC are diagnosed at an advanced or metastatic stage of disease.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients

Zhang

Rong

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Lung cancer is the most common malignant tumor worldwide. MicroRNA has become an ideal biomarker for cancer diagnosis, prognosis and therapy. The relationship between microRNA-141 and non-small cell lung cancer (NSCLC) is contradictory. Thus, in current study, we aimed to investigate the level of microRNA-141 in NSCLC tissues and to evaluate its potential clinical value. This study enrolled 125 NSCLC patients (75 males and 50 females) with a median age of 61 years (range, 23-90 years). NSCLC patients included 23 squamous cell carcinomas (SCCs), 101 adenocarcinomas (ADCs) and 1 large cell carcinoma. The expression level of microRNA-141 was significantly higher in NSCLC tissues than in adjacent lung tissues (P < 0.001), detected by real time RT-PCR. Receiver operating characteristic (ROC) exhibited a moderate diagnostic value of microRNA-141 for NSCLC with the area under curve of 0.707. The microRNA-141 expression increased with the larger tumor size (P = 0.002), lymph node metastasis (P = 0.018) and advanced stage (P = 0.022) in NSCLC patients. For subgroup analysis, microRNA-141 expression in SCC was correlated with tumor size (r = 0.490, P = 0.018), and in ADC, microRNA-141 level was positively associated with tumor size (r = 0.222, P = 0.026), lymph node metastasis (r = 0.242, P = 0.015) and TNM stage (r = 0.210, P = 0.035). Furthermore, univariate analysis revealed that the expression of microRNA-141 was an independent prognostic indicator of ADC. In conclusion, microRNA-141 is a potential biomarker for the molecular diagnosis and risk stratification of NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients

Zhang

Rong

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…In China, lung cancer is the first leading cause of death from all cancers (Chen et al,additional therapy. However, the specific markers have not been achievable (Chen et al, 2012;Chen et al, 2013a;2013b;2013c;Gazala et al, 2013;Granger et al, 2013). Therefore, the research for effective molecular markers for diagnosis and treatment of lung cancer is an important issue at present.…”

Section: Introductionmentioning

confidence: 99%

Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues

Zhang¹,

Dang²,

Li³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The VATS lobectomy resulted in a lower total complication rate (OR 0.45, 95% CI 0.24-0.84; p = 0.013) compared to the open lobectomy based on the data including a total of 23 studies [24]. Based on a systemic review and meta-analysis of the assessment of PROs after the lung cancer surgery [25], patients undergoing VATS have a better HR-QOL when compared to patients who receiving the thoracotomy. The consistent use of a lung cancer specific questionnaire for measuring the HR-QOL after surgery was reported to be encouraging [25].…”

Section: Discussionmentioning

confidence: 99%

“…Based on a systemic review and meta-analysis of the assessment of PROs after the lung cancer surgery [25], patients undergoing VATS have a better HR-QOL when compared to patients who receiving the thoracotomy. The consistent use of a lung cancer specific questionnaire for measuring the HR-QOL after surgery was reported to be encouraging [25].…”

Section: Discussionmentioning

confidence: 99%

Patient-Reported Outcomes of Surgery of Non-Small Cell Lung Cancer: Evaluation Based on the Questionnaires of Anti-Aging Quality of Life and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire

Ayabe¹,

Tomita²,

Nose³

et al. 2017

View full text Add to dashboard Cite

Background: Patient-reported outcomes of the quality of life (QOL) after an open thoracotomy have not been studied. To determine the physical and mental changes in surgical patients is very important for medical staffs. The surgical patient's satisfaction and overall healthy changes were evaluated by the patient-self assessment questionnaires. Materials and Methods: From July 2007 to April 2008, 26 patients with non-small cell lung cancer (NSCLC) underwent surgical resection. The outcome of the QOL was evaluated by using two kinds of questionnaire surveys from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the anti-aging QOL assessment (AA-QOL). The EORTC QLQ-C30 consisted of five domains (physical, role, cognitive, emotional, and social functionings) and global QOL. The AA-QOL contained 51 items; 30 physical and 21 mental symptoms regarding the elderly and the aging population. The patients replied to the two questionnaires at two different times, i.e., at pre-surgery (baseline) and at post-surgery (2 weeks after the operation). The obtained data of these scores were averaged and compared between the two points of the pre-surgery and post-surgery. Results: Regarding the outcomes of the EORTC QLQ-C30, the physical and social functioning became significantly worse after the surgery. In contrast, the global QOL significantly became better after the surgery. For the symptom at post-surgery, three of which were "nausea and vomiting", "pain", and "appetite loss", became significantly worse compared to those at pre-surgery. Regarding the outcomes of How to cite this paper: Ayabe, T., Tomita, M., Nose, N., Asada, T. and Nakamura, K. 204the AA-QOL, the physical symptoms (muscular pain/stiffness, palpitations, dyspnea, no feeling of good health, anorexia, and coughing and sputum) became significantly worse after the surgery. Regarding the mental symptoms, there were no significant differences. Conclusions: Regarding the outcomes based on the changes in the QOL after surgery, the physical symptoms became worse compared to the mental symptoms. To clarify the perioperative healthy changes of the QOL reported by patients with lung cancers is very important for multidisciplinary teamwork, which should play a role in providing the appropriate care and treatment and useful information for a preoperative patient's decision making of receiving surgical treatment.

show abstract

A Systematic Review and Meta‐Analysis to Assess Patient‐Reported Outcomes after Lung Cancer Surgery

Cited by 24 publications

References 11 publications

MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients

MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients

Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues

Patient-Reported Outcomes of Surgery of Non-Small Cell Lung Cancer: Evaluation Based on the Questionnaires of Anti-Aging Quality of Life and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire

Contact Info

Product

Resources

About